This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon Announces First Quarter 2014 Results

Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2014. Net product revenue for the quarter was $68.8 million compared to $67.6 million in the first quarter of 2013. Net loss in the first quarter of 2014 was $36.4 million, or $0.24 per share, compared to a net loss of $72.0 million, or $0.48 per share for the same period in 2013. As of March 31, 2014, Dendreon had approximately $170 million in cash, cash equivalents, and short-term and long-term investments.

John H. Johnson, chairman, president and chief executive officer of Dendreon, said, “This was the first quarter since the introduction of competition where we saw revenues grow as compared to the prior year, which confirms the progress we are making on a year-over-year basis. Achieving our first quarter results with fewer headcount, reduced expenses and streamlined marketing spend compared to the first quarter of last year speaks to our more efficient use of resources. We continue to work to accelerate our path to profitability, and remain focused on becoming cash flow breakeven as soon as possible.”

“During the first quarter, we saw our enrollments increase on a sequential basis. After stabilizing PROVENGE sales in the face of competition, we expect the second quarter to improve from the first quarter, as it did last year,” Mr. Johnson continued. “With the increasing amount of data surrounding PROVENGE along with a broader understanding of immunotherapy in cancer, we continue to see KOL support strengthening for PROVENGE, particularly in Europe following a successful European Association of Urology (EAU) meeting and the inclusion of PROVENGE in the new EAU prostate cancer guidelines.”

Recent Highlights:
  • PROVENGE ® (sipuleucel-T) sales have continued to stabilize
    • Community urology, a key focus area, grew 28% overall year over year
  • Cost of goods sold was approximately $37 million, or 53% of revenue, down from approximately $43 million or 64% of revenue in the first quarter of 2013
  • Sales, general, and administrative expenses were approximately $39 million, down from approximately $62 million in the first quarter of 2013
  • Cash burn was $30 million, down significantly from the first quarter of 2013 and down slightly from the fourth quarter of 2013
  • Continued focus on targeted accounts
    • 93 large accounts, up significantly from 54 in the first quarter of 2013
  • Competitive environment continued to evolve
    • Zytiga and Xtandi increasing competitive share in post-chemo setting
    • Increased competition in pre-chemo in oncology from Xtandi
    • Continue to see greatest impact of competition in small and low volume accounts across our market segments
  • Continued progress to make PROVENGE commercially available in Europe
    • Making PROVENGE available through Centers of Excellence, beginning with fewer than 10 centers
    • Goal is to have the first commercial patient treated in the fourth quarter of 2014
    • Preparing for discussions with European regulatory authorities regarding automation
    • Plan to expand further beyond Centers of Excellence once automation is approved
    • Inclusion of PROVENGE in the new EAU prostate cancer treatment guidelines, which recommend PROVENGE as a therapeutic option for patients with asymptomatic, minimally symptomatic mCRPC and support the fact that there was a significant overall survival benefit in the PROVENGE arm in the pivotal study, with an overall safety profile that was acceptable
    • Continued momentum with successful EAU meeting and strong KOL support; in addition, 70% of a panel of physicians in the European Journal of Cancer agreed that PROVENGE should be used prior to Xtandi and Zytiga
  • Addressing the Company’s convertible debt remains a top priority and the Company is exploring its options with advisors
  • Presented data from ongoing immuno-oncology trials at ASCO-GU, which further elucidate the product potency and mechanism of PROVENGE, in addition to investigational compound DN24-02 for the treatment of urothelial carcinoma
  • Completed enrollment in randomized Phase II study in high-risk urothelial carcinoma
  • Presented preliminary data from Phase II STAND study at the 29th Annual EAU Congress

Conference Call Information

Dendreon will host a conference call on May 8, 2014 at 9:00 a.m. ET. To access the live call, dial 1-877-548-9590 (domestic) or +1-720-545-0037 (international); the conference ID number is 35049713. The call will also be audio webcast from the Company’s website at under the “Investor/Webcasts and Presentations” section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-855-859-2056 or +1-404-537-3406 for international callers; the conference ID number is 35049713. The replay will be available from 12:00 p.m. EST on Thursday, May 8, 2014, until 11:59 p.m. EST on Thursday, May 15, 2014. In addition, the webcast will be archived for on-demand listening for 90 days at

PROVENGE Indication and Important Safety Information

PROVENGE ® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis. The most common adverse events (incidence greater-than or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.18 0.51%
FB $103.10 1.20%
GOOG $688.60 0.80%
TSLA $150.56 0.06%
YHOO $27.05 1.10%


Chart of I:DJI
DOW 15,888.51 +228.33 1.46%
S&P 500 1,849.72 +20.64 1.13%
NASDAQ 4,298.3630 +31.5260 0.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs